vs
Side-by-side financial comparison of Guardant Health, Inc. (GH) and INTERFACE INC (TILE). Click either name above to swap in a different company.
INTERFACE INC is the larger business by last-quarter revenue ($349.4M vs $281.3M, roughly 1.2× Guardant Health, Inc.). INTERFACE INC runs the higher net margin — 7.0% vs -45.7%, a 52.7% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs 4.3%). INTERFACE INC produced more free cash flow last quarter ($28.6M vs $-54.2M). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs 9.8%).
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
Interface, Inc., headquartered in Atlanta, Georgia, is a global manufacturer of commercial flooring. The company sells modular carpet tiles, luxury vinyl tile, and Nora brand rubber flooring.
GH vs TILE — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $281.3M | $349.4M |
| Net Profit | $-128.5M | $24.4M |
| Gross Margin | 64.6% | 38.6% |
| Operating Margin | -43.0% | 10.1% |
| Net Margin | -45.7% | 7.0% |
| Revenue YoY | 39.4% | 4.3% |
| Net Profit YoY | -15.8% | 12.1% |
| EPS (diluted) | $-1.01 | $0.41 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $281.3M | $349.4M | ||
| Q3 25 | $265.2M | $364.5M | ||
| Q2 25 | $232.1M | $375.5M | ||
| Q1 25 | $203.5M | $297.4M | ||
| Q4 24 | $201.8M | $335.0M | ||
| Q3 24 | $191.5M | $344.3M | ||
| Q2 24 | $177.2M | $346.6M | ||
| Q1 24 | $168.5M | $289.7M |
| Q4 25 | $-128.5M | $24.4M | ||
| Q3 25 | $-92.7M | $46.1M | ||
| Q2 25 | $-99.9M | $32.6M | ||
| Q1 25 | $-95.2M | $13.0M | ||
| Q4 24 | $-111.0M | $21.8M | ||
| Q3 24 | $-107.8M | $28.4M | ||
| Q2 24 | $-102.6M | $22.6M | ||
| Q1 24 | $-115.0M | $14.2M |
| Q4 25 | 64.6% | 38.6% | ||
| Q3 25 | 64.7% | 39.4% | ||
| Q2 25 | 65.0% | 39.4% | ||
| Q1 25 | 63.3% | 37.3% | ||
| Q4 24 | 61.6% | 36.5% | ||
| Q3 24 | 61.1% | 37.1% | ||
| Q2 24 | 59.1% | 35.4% | ||
| Q1 24 | 61.2% | 38.1% |
| Q4 25 | -43.0% | 10.1% | ||
| Q3 25 | -37.3% | 14.6% | ||
| Q2 25 | -45.9% | 13.9% | ||
| Q1 25 | -54.6% | 7.8% | ||
| Q4 24 | -62.4% | 8.8% | ||
| Q3 24 | -61.3% | 12.3% | ||
| Q2 24 | -56.8% | 11.0% | ||
| Q1 24 | -59.2% | 8.4% |
| Q4 25 | -45.7% | 7.0% | ||
| Q3 25 | -35.0% | 12.7% | ||
| Q2 25 | -43.0% | 8.7% | ||
| Q1 25 | -46.8% | 4.4% | ||
| Q4 24 | -55.0% | 6.5% | ||
| Q3 24 | -56.3% | 8.3% | ||
| Q2 24 | -57.9% | 6.5% | ||
| Q1 24 | -68.2% | 4.9% |
| Q4 25 | $-1.01 | $0.41 | ||
| Q3 25 | $-0.74 | $0.78 | ||
| Q2 25 | $-0.80 | $0.55 | ||
| Q1 25 | $-0.77 | $0.22 | ||
| Q4 24 | $-0.90 | $0.38 | ||
| Q3 24 | $-0.88 | $0.48 | ||
| Q2 24 | $-0.84 | $0.38 | ||
| Q1 24 | $-0.94 | $0.24 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $378.2M | $71.3M |
| Total DebtLower is stronger | $1.5B | $181.6M |
| Stockholders' EquityBook value | $-99.3M | $640.7M |
| Total Assets | $2.0B | $1.2B |
| Debt / EquityLower = less leverage | — | 0.28× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $378.2M | $71.3M | ||
| Q3 25 | $580.0M | $187.4M | ||
| Q2 25 | $629.1M | $121.7M | ||
| Q1 25 | $698.6M | $97.8M | ||
| Q4 24 | $525.5M | $99.2M | ||
| Q3 24 | $585.0M | $115.6M | ||
| Q2 24 | $933.7M | $94.2M | ||
| Q1 24 | $1.0B | $89.8M |
| Q4 25 | $1.5B | $181.6M | ||
| Q3 25 | $1.1B | $307.8M | ||
| Q2 25 | $1.1B | $304.4M | ||
| Q1 25 | $1.1B | $302.9M | ||
| Q4 24 | $1.1B | $302.8M | ||
| Q3 24 | — | $337.9M | ||
| Q2 24 | — | $387.6M | ||
| Q1 24 | — | $391.8M |
| Q4 25 | $-99.3M | $640.7M | ||
| Q3 25 | $-354.5M | $621.0M | ||
| Q2 25 | $-305.5M | $575.0M | ||
| Q1 25 | $-250.8M | $513.1M | ||
| Q4 24 | $-139.6M | $489.1M | ||
| Q3 24 | $-60.1M | $501.6M | ||
| Q2 24 | $-1.6M | $451.2M | ||
| Q1 24 | $68.3M | $428.5M |
| Q4 25 | $2.0B | $1.2B | ||
| Q3 25 | $1.3B | $1.3B | ||
| Q2 25 | $1.3B | $1.3B | ||
| Q1 25 | $1.3B | $1.2B | ||
| Q4 24 | $1.5B | $1.2B | ||
| Q3 24 | $1.5B | $1.2B | ||
| Q2 24 | $1.6B | $1.2B | ||
| Q1 24 | $1.7B | $1.2B |
| Q4 25 | — | 0.28× | ||
| Q3 25 | — | 0.50× | ||
| Q2 25 | — | 0.53× | ||
| Q1 25 | — | 0.59× | ||
| Q4 24 | — | 0.62× | ||
| Q3 24 | — | 0.67× | ||
| Q2 24 | — | 0.86× | ||
| Q1 24 | — | 0.91× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-26.4M | $49.3M |
| Free Cash FlowOCF − Capex | $-54.2M | $28.6M |
| FCF MarginFCF / Revenue | -19.3% | 8.2% |
| Capex IntensityCapex / Revenue | 9.9% | 5.9% |
| Cash ConversionOCF / Net Profit | — | 2.02× |
| TTM Free Cash FlowTrailing 4 quarters | $-233.1M | $121.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-26.4M | $49.3M | ||
| Q3 25 | $-35.4M | $76.7M | ||
| Q2 25 | $-60.3M | $30.1M | ||
| Q1 25 | $-62.7M | $11.7M | ||
| Q4 24 | $-64.5M | $38.0M | ||
| Q3 24 | $-51.1M | $76.2M | ||
| Q2 24 | $-94.0M | $21.5M | ||
| Q1 24 | $-30.3M | $12.6M |
| Q4 25 | $-54.2M | $28.6M | ||
| Q3 25 | $-45.8M | $66.1M | ||
| Q2 25 | $-65.9M | $22.8M | ||
| Q1 25 | $-67.1M | $4.3M | ||
| Q4 24 | $-83.4M | $24.4M | ||
| Q3 24 | $-55.3M | $69.7M | ||
| Q2 24 | $-99.1M | $12.0M | ||
| Q1 24 | $-37.2M | $8.6M |
| Q4 25 | -19.3% | 8.2% | ||
| Q3 25 | -17.3% | 18.1% | ||
| Q2 25 | -28.4% | 6.1% | ||
| Q1 25 | -33.0% | 1.4% | ||
| Q4 24 | -41.3% | 7.3% | ||
| Q3 24 | -28.9% | 20.3% | ||
| Q2 24 | -55.9% | 3.5% | ||
| Q1 24 | -22.1% | 3.0% |
| Q4 25 | 9.9% | 5.9% | ||
| Q3 25 | 3.9% | 2.9% | ||
| Q2 25 | 2.4% | 2.0% | ||
| Q1 25 | 2.2% | 2.5% | ||
| Q4 24 | 9.4% | 4.1% | ||
| Q3 24 | 2.2% | 1.9% | ||
| Q2 24 | 2.9% | 2.8% | ||
| Q1 24 | 4.1% | 1.4% |
| Q4 25 | — | 2.02× | ||
| Q3 25 | — | 1.66× | ||
| Q2 25 | — | 0.93× | ||
| Q1 25 | — | 0.90× | ||
| Q4 24 | — | 1.75× | ||
| Q3 24 | — | 2.68× | ||
| Q2 24 | — | 0.95× | ||
| Q1 24 | — | 0.89× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
TILE
| AMS | $205.9M | 59% |
| EAAA | $143.5M | 41% |
